OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation.

doi:10.64719/pb.4546

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation.

Psychopharmacology bulletin - 4 Jul 2025

Skryabin Valentin, Miroshkin Sergei, Masyakin Anton, Pozdniakov Sergei, Ivanchenko Valentina, Shipitsin Valery

Abstract excerpt

Alcohol use disorder (AUD) remains a major contributor to the global burden of disease. Extended-release naltrexone (XR-NTX), a μ-opioid receptor antagonist, is a key pharmacological option for maintaining abstinence, though individual treatment response varies substantially. Genetic variability in the μ-opioid receptor gene (OPRM1), particularly rs1799971, may underpin this heterogeneity. Study objective was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Delayed-Action Preparations

Share to Motivation

Share to Naltrexone

Share to Narcotic Antagonists

Share to Polymorphism, Single Nucleotide

Share to Receptors, Opioid, mu

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 40630969
DOI: 10.64719/pb.4546
PMCID: PMC12233936

Genes

OPRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation.PMID 40630969Read ↗

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.Semantic proximity Read ↗

Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial.Semantic proximity Read ↗

Opioid pharmacogenetics of alcohol addiction.Semantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.Semantic proximity Read ↗

Genetic Contributions to Alcohol Use Disorder Treatment Outcomes: A Genome-wide Pharmacogenomics StudySemantic proximity Read ↗

[OPRD1 gene polymorphism (rs4654327) as a potential predictor of the effectiveness of long-acting naltrexone in patients with alcohol addiction].Semantic proximity Read ↗

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.Semantic proximity Read ↗

OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.Semantic proximity Read ↗

Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics studySemantic proximity Read ↗

Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.Semantic proximity Read ↗

COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.